IP Library › Granted Patent US 10,364,290

Granted Patent B2

US 10,364,290 · App. 15/668,396 · Granted Jul 30, 2019

Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4

Inventors: Birgit Bossenmaier (Seefeld, DE); Guy Georges (Habach, DE); Michael Gerg (Munich, DE); Gerhard Niederfellner (Oberhausen, DE); Christian Scholz (Penzberg, DE); Michael Schraeml (Penzberg, DE)

Assignee: Hoffmann-La Roche Inc.

C07K16/2863 A61K47/6803 A61K47/6829 A61K47/6851 A61K47/6855 C07K16/32 A61K2039/505 C07K2317/24 C07K2317/33 C07K2317/34 C07K2317/55 C07K2317/73 C07K2317/75 C07K2317/77

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,364,290
App. No.: 15/668,396
Granted: Jul 30, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Claims (81)

1. An isolated nucleic acid encoding an antibody that binds to human HER3 and binds to human HER4, wherein the antibody comprises:

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

2. An isolated nucleic acid encoding an antibody that binds to human HER3 and binds to human HER4, wherein the antibody is selected from the group consisting of

i) an antibody comprising:

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30;

ii) an antibody comprising:

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30;

iii) an antibody comprising:

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30;

and

iv) an antibody comprising:

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

3. An isolated nucleic acid encoding an antibody that binds to human HER3 and binds to human HER4, wherein the antibody is selected from the group consisting of

a) an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:36;

b) an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:37;

c) an antibody comprising a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:36;

d) an antibody comprising a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:37;

e) an antibody comprising a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:36; and

f) an antibody comprising a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:37.

4. The isolated nucleic acid of claim 2 , wherein nucleic acid encodes an antibody comprising

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

5. The isolated nucleic acid of claim 2 , wherein nucleic acid encodes an antibody comprising

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

6. The isolated nucleic acid of claim 2 , wherein nucleic acid encodes an antibody comprising

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

7. The isolated nucleic acid of claim 2 , wherein nucleic acid encodes an antibody comprising

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25,

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39,

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40,

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

8. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:36.

9. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:37.

10. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:36.

11. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:37.

12. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:36.

13. The isolated nucleic acid of claim 3 , wherein nucleic acid encodes an antibody comprising a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:37.

14. A host cell comprising the nucleic acid of any one of claims 1 - 13 .

15. A method of producing an antibody comprising culturing the host cell of claim 11 so that the antibody is produced, and recovering said antibody from said cell culture or the cell culture supernatant.

16. The method of claim 15 further comprising recovering said antibody from said cell culture or the cell culture supernatant.

Priority Claims (1)

EP 12191871 · Nov 8, 2012 · regional

Continuity (2)

Division 14073137 · Nov 6, 2013

Related Publication 20180118837A1 · May 3, 2018